Alnylam Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Alnylam Pharmaceuticals
ALNY Stock  USD 253.07  0.67  0.26%   
Alnylam Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Alnylam Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Alnylam Pharmaceuticals financial statements helps investors assess Alnylam Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Alnylam Pharmaceuticals' valuation are summarized below:
Gross Profit
868.6 M
Profit Margin
(0.16)
Market Capitalization
32.7 B
Enterprise Value Revenue
14.8763
Revenue
2.1 B
We have found one hundred twenty available fundamental signals for Alnylam Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Alnylam Pharmaceuticals prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 3.1 M in 2024. Enterprise Value is likely to drop to about (18.9 M) in 2024

Alnylam Pharmaceuticals Total Revenue

1.92 Billion

Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 56.8 M, Interest Expense of 127.3 M or Other Operating Expenses of 2.2 B, as well as many indicators such as Price To Sales Ratio of 12.42, Dividend Yield of 0.0 or Days Sales Outstanding of 63.31. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Alnylam Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4 B3.8 B1.9 B
Slightly volatile
Other Current Liabilities748.7 M713 M221.9 M
Slightly volatile
Total Current Liabilities1 B967.8 M483.4 M
Slightly volatile
Property Plant And Equipment Net762.1 M725.8 M335.4 M
Slightly volatile
Accounts Payable28.9 M55.5 M36.6 M
Slightly volatile
Cash853.3 M812.7 M533.9 M
Slightly volatile
Non Current Assets Total889.5 M847.2 M422.8 M
Slightly volatile
Cash And Short Term Investments2.6 B2.4 B1.3 B
Slightly volatile
Common Stock Shares Outstanding70.4 M124.9 M83.3 M
Slightly volatile
Short Term Investments1.7 B1.6 B751.5 M
Slightly volatile
Liabilities And Stockholders Equity4 B3.8 B1.9 B
Slightly volatile
Non Current Liabilities Total3.2 B3.1 B911.3 M
Slightly volatile
Other Current Assets94.5 M126.4 M107.5 M
Slightly volatile
Total Liabilities4.3 B4.1 B1.3 B
Slightly volatile
Property Plant And Equipment Gross996.3 M948.9 M351.1 M
Slightly volatile
Total Current Assets3.1 B3 B1.5 B
Slightly volatile
Property Plant Equipment632.1 M602 M257.9 M
Slightly volatile
Short and Long Term Debt Total2.8 B2.7 B649.8 M
Slightly volatile
Other Liabilities490.7 M467.3 M267.9 M
Slightly volatile
Current Deferred Revenue119.3 M102.8 M129.5 M
Slightly volatile
Other Stockholder Equity7.2 B6.8 B3.6 B
Slightly volatile
Short Term Debt101.3 M96.5 M58.6 M
Slightly volatile
Net Receivables344.2 M327.8 M92.3 M
Slightly volatile
Common Stock Total Equity770.9 K1.4 M880.8 K
Slightly volatile
Common Stock801.6 K1.3 M871.7 K
Slightly volatile
Capital Surpluse7.8 B7.4 B3.8 B
Slightly volatile
Deferred Long Term Liabilities60.8 M52.1 M68.6 M
Slightly volatile
Non Current Liabilities Other1.7 B1.6 B581.9 M
Slightly volatile
Deferred Long Term Asset Charges25.3 M28.5 M31 M
Slightly volatile
Long Term Debt Total1.2 B1.2 B372.2 M
Slightly volatile
Short and Long Term Debt25.6 M27 M85.5 M
Slightly volatile
Net Invested Capital994 M800.1 M1.5 B
Slightly volatile
Net Working Capital1.8 B2 B1.7 B
Slightly volatile
Capital Stock1.3 M1.3 M1.1 M
Slightly volatile
Capital Lease Obligations247 M284.6 M301.7 M
Slightly volatile

Alnylam Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization56.8 M54.1 M25.1 M
Slightly volatile
Other Operating Expenses2.2 B2.1 B874.6 M
Slightly volatile
Research Development1.1 B1 B472.8 M
Slightly volatile
Total Operating Expenses1.9 B1.8 B804.6 M
Slightly volatile
Selling General Administrative835.4 M795.6 M332.2 M
Slightly volatile
Total Revenue1.9 B1.8 B456.2 M
Slightly volatile
Gross Profit1.6 B1.5 B386.2 M
Slightly volatile
Cost Of Revenue178.7 M310.4 M194.2 M
Very volatile
Non Recurring176.6 M198.7 M216.4 M
Slightly volatile
Interest Income100.3 M95.6 M23.5 M
Slightly volatile
Reconciled Depreciation66.1 M97 M38.7 M
Slightly volatile
Extraordinary Items640 K720 K784 K
Slightly volatile

Alnylam Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation101.9 M97 M39.6 M
Slightly volatile
Capital Expenditures40 M62.2 M52.9 M
Slightly volatile
Total Cash From Financing Activities163.5 M172.1 M457.3 M
Slightly volatile
End Period Cash Flow855.6 M814.9 M407.9 M
Slightly volatile
Stock Based Compensation232.8 M221.7 M108.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.4213.076861.8334
Pretty Stable
Days Sales Outstanding63.3165.439490.4871
Very volatile
Stock Based Compensation To Revenue0.120.12120.6689
Pretty Stable
Capex To Depreciation0.610.64113.7906
Pretty Stable
Inventory Turnover3.663.4820.7705
Slightly volatile
Days Of Inventory On Hand99.58105462
Pretty Stable
Payables Turnover5.875.5911.3931
Slightly volatile
Sales General And Administrative To Revenue0.410.43521.4511
Pretty Stable
Average Inventory11.4 M10.8 M7.1 M
Slightly volatile
Research And Ddevelopement To Revenue0.520.54947.7444
Slightly volatile
Capex To Revenue0.03230.0341.5779
Slightly volatile
Cash Per Share10.3419.529714.7458
Very volatile
Days Payables Outstanding62.0265.28361.3 K
Very volatile
Current Ratio5.833.0825.3566
Slightly volatile
Receivables Turnover5.35.577750.4674
Slightly volatile
Graham Number11.2411.835930.1161
Pretty Stable
Capex Per Share0.70.49810.6486
Pretty Stable
Revenue Per Share15.3714.63733.9765
Slightly volatile
Interest Debt Per Share21.1820.16915.9092
Slightly volatile
Debt To Assets0.660.62610.2283
Slightly volatile
Operating Cycle162170571
Pretty Stable
Days Of Payables Outstanding62.0265.28361.3 K
Very volatile
Ebt Per Ebit0.831.53631.0637
Slightly volatile
Quick Ratio2.842.98995.6399
Slightly volatile
Net Income Per E B T0.781.01550.956
Pretty Stable
Cash Ratio0.80.83972.4986
Slightly volatile
Days Of Inventory Outstanding99.58105462
Pretty Stable
Days Of Sales Outstanding63.3165.439490.4871
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.380.40271.0712
Slightly volatile
Fixed Asset Turnover2.42.5191.6921
Pretty Stable
Debt Ratio0.660.62610.2283
Slightly volatile
Price Sales Ratio12.4213.076861.8334
Pretty Stable
Asset Turnover0.50.47740.1725
Slightly volatile
Gross Profit Margin0.960.83020.865
Pretty Stable

Alnylam Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.1 M5.1 M5.2 M
Very volatile

Alnylam Fundamental Market Drivers

Forward Price Earnings909.0909
Cash And Short Term Investments2.4 B

Alnylam Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue102.8 M119.3 M
Total Revenue1.8 B1.9 B
Cost Of Revenue310.4 M178.7 M
Stock Based Compensation To Revenue 0.12  0.12 
Sales General And Administrative To Revenue 0.44  0.41 
Research And Ddevelopement To Revenue 0.55  0.52 
Capex To Revenue 0.03  0.03 
Revenue Per Share 14.64  15.37 
Ebit Per Revenue(0.15)(0.16)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY